Identification  ||| S:0 E:15 ||| NN
of  ||| S:15 E:18 ||| IN
novel  ||| S:18 E:24 ||| JJ
therapeutic  ||| S:24 E:36 ||| JJ
targets  ||| S:36 E:44 ||| NNS
in  ||| S:44 E:47 ||| IN
the  ||| S:47 E:51 ||| DT
secretome  ||| S:51 E:61 ||| NN
of  ||| S:61 E:64 ||| IN
ionizing  ||| S:64 E:73 ||| FW
radiation‑induced  ||| S:73 E:91 ||| FW
senescent  ||| S:91 E:101 ||| FW
tumor  ||| S:101 E:107 ||| FW
cells  ||| S:107 E:113 ||| FW
Cellular  ||| S:113 E:122 ||| FW
senescence  ||| S:122 E:133 ||| FW
is  ||| S:133 E:136 ||| VBZ
a  ||| S:136 E:138 ||| DT
state  ||| S:138 E:144 ||| NN
of  ||| S:144 E:147 ||| IN
irreversible  ||| S:147 E:160 ||| JJ
growth  ||| S:160 E:167 ||| NN
arrest  ||| S:167 E:174 ||| NN
that  ||| S:174 E:179 ||| WDT
can  ||| S:179 E:183 ||| MD
be  ||| S:183 E:186 ||| VB
triggered  ||| S:186 E:196 ||| VBN
by  ||| S:196 E:199 ||| IN
multiple  ||| S:199 E:208 ||| JJ
mechanisms ||| S:208 E:218 ||| NNS
,  ||| S:218 E:220 ||| ,
including  ||| S:220 E:230 ||| VBG
telomere  ||| S:230 E:239 ||| JJ
shortening ||| S:239 E:249 ||| NN
,  ||| S:249 E:251 ||| ,
the  ||| S:251 E:255 ||| DT
epigenetic  ||| S:255 E:266 ||| JJ
derepression  ||| S:266 E:279 ||| NN
of  ||| S:279 E:282 ||| IN
the  ||| S:282 E:286 ||| DT
INK4α ||| S:286 E:291 ||| NNP
/ ||| S:291 E:292 ||| NNP
ARF  ||| S:292 E:296 ||| NNP
locus  ||| S:296 E:302 ||| NN
and  ||| S:302 E:306 ||| CC
DNA  ||| S:306 E:310 ||| NNP
damage ||| S:310 E:316 ||| NN
.  ||| S:316 E:318 ||| .
Senescence  ||| S:318 E:329 ||| NNP
has  ||| S:329 E:333 ||| VBZ
been  ||| S:333 E:338 ||| VBN
considered  ||| S:338 E:349 ||| VBN
a  ||| S:349 E:351 ||| DT
tumor‑suppressing  ||| S:351 E:369 ||| JJ
mechanism  ||| S:369 E:379 ||| NN
that  ||| S:379 E:384 ||| WDT
permanently  ||| S:384 E:396 ||| RB
arrests  ||| S:396 E:404 ||| JJ
cells  ||| S:404 E:410 ||| NNS
at  ||| S:410 E:413 ||| IN
risk  ||| S:413 E:418 ||| NN
for  ||| S:418 E:422 ||| IN
malignant  ||| S:422 E:432 ||| JJ
transformation ||| S:432 E:446 ||| NN
.  ||| S:446 E:448 ||| .
However ||| S:448 E:455 ||| RB
,  ||| S:455 E:457 ||| ,
accumulating  ||| S:457 E:470 ||| VBG
evidence  ||| S:470 E:479 ||| NN
shows  ||| S:479 E:485 ||| NNS
that  ||| S:485 E:490 ||| IN
senescent  ||| S:490 E:500 ||| JJ
cells  ||| S:500 E:506 ||| NNS
have  ||| S:506 E:511 ||| VBP
deleterious  ||| S:511 E:523 ||| JJ
effects  ||| S:523 E:531 ||| NNS
on  ||| S:531 E:534 ||| IN
the  ||| S:534 E:538 ||| DT
tissue  ||| S:538 E:545 ||| NN
microenvironment ||| S:545 E:561 ||| NN
.  ||| S:561 E:563 ||| .
Some  ||| S:563 E:568 ||| DT
of  ||| S:568 E:571 ||| IN
these  ||| S:571 E:577 ||| DT
effects  ||| S:577 E:585 ||| NNS
could  ||| S:585 E:591 ||| MD
be  ||| S:591 E:594 ||| VB
attributed  ||| S:594 E:605 ||| VBN
to  ||| S:605 E:608 ||| TO
the  ||| S:608 E:612 ||| DT
senescence‑associated  ||| S:612 E:634 ||| CD
secretory  ||| S:634 E:644 ||| CD
phenotype  ||| S:644 E:654 ||| NNS
that  ||| S:654 E:659 ||| WDT
has  ||| S:659 E:663 ||| VBZ
the  ||| S:663 E:667 ||| DT
ability  ||| S:667 E:675 ||| NN
to  ||| S:675 E:678 ||| TO
promote  ||| S:678 E:686 ||| VB
tumor  ||| S:686 E:692 ||| NN
progression ||| S:692 E:703 ||| NN
.  ||| S:703 E:705 ||| .
However ||| S:705 E:712 ||| RB
,  ||| S:712 E:714 ||| ,
secreted  ||| S:714 E:723 ||| JJ
proteins  ||| S:723 E:732 ||| NNS
from  ||| S:732 E:737 ||| IN
senescent  ||| S:737 E:747 ||| JJ
tumor  ||| S:747 E:753 ||| NN
cells  ||| S:753 E:759 ||| NNS
and  ||| S:759 E:763 ||| CC
their  ||| S:763 E:769 ||| PRP$
effects  ||| S:769 E:777 ||| NNS
on  ||| S:777 E:780 ||| IN
the  ||| S:780 E:784 ||| DT
tumor  ||| S:784 E:790 ||| NN
microenvironment  ||| S:790 E:807 ||| VBZ
due  ||| S:807 E:811 ||| JJ
to  ||| S:811 E:814 ||| TO
ionizing  ||| S:814 E:823 ||| VB
radiation  ||| S:823 E:833 ||| NN
( ||| S:833 E:834 ||| -LRB-
IR ||| S:834 E:836 ||| NNP
)  ||| S:836 E:838 ||| -RRB-
exposure  ||| S:838 E:847 ||| NN
have  ||| S:847 E:852 ||| VBP
not  ||| S:852 E:856 ||| RB
yet  ||| S:856 E:860 ||| RB
been  ||| S:860 E:865 ||| VBN
fully  ||| S:865 E:871 ||| RB
elucidated ||| S:871 E:881 ||| VBN
.  ||| S:881 E:883 ||| .
In  ||| S:883 E:886 ||| IN
the  ||| S:886 E:890 ||| DT
present  ||| S:890 E:898 ||| JJ
study ||| S:898 E:903 ||| NN
,  ||| S:903 E:905 ||| ,
we  ||| S:905 E:908 ||| PRP
analyzed  ||| S:908 E:917 ||| VBD
cytokines  ||| S:917 E:927 ||| JJ
secreted  ||| S:927 E:936 ||| NN
from  ||| S:936 E:941 ||| IN
IR‑induced  ||| S:941 E:952 ||| CD
senescent  ||| S:952 E:962 ||| CD
MCF7  ||| S:962 E:967 ||| CD
cells  ||| S:967 E:973 ||| NNS
by  ||| S:973 E:976 ||| IN
using  ||| S:976 E:982 ||| VBG
cytokine  ||| S:982 E:991 ||| JJ
microarrays  ||| S:991 E:1003 ||| NN
and  ||| S:1003 E:1007 ||| CC
confirmed  ||| S:1007 E:1017 ||| VBD
by  ||| S:1017 E:1020 ||| IN
western  ||| S:1020 E:1028 ||| JJ
blot  ||| S:1028 E:1033 ||| JJ
analysis  ||| S:1033 E:1042 ||| NN
that  ||| S:1042 E:1047 ||| WDT
increased  ||| S:1047 E:1057 ||| VBD
secretion  ||| S:1057 E:1067 ||| VBN
of  ||| S:1067 E:1070 ||| IN
osteoprotegerin  ||| S:1070 E:1086 ||| NNS
( ||| S:1086 E:1087 ||| -LRB-
OPG ||| S:1087 E:1090 ||| NNP
) ||| S:1090 E:1091 ||| -RRB-
,  ||| S:1091 E:1093 ||| ,
midkine  ||| S:1093 E:1101 ||| NNP
( ||| S:1101 E:1102 ||| -LRB-
MDK ||| S:1102 E:1105 ||| NNP
)  ||| S:1105 E:1107 ||| -RRB-
and  ||| S:1107 E:1111 ||| CC
apolipoprotein E3  ||| S:1111 E:1129 ||| NNP
( ||| S:1129 E:1130 ||| -LRB-
ApoE3 ||| S:1130 E:1135 ||| NNP
)  ||| S:1135 E:1137 ||| -RRB-
occurs  ||| S:1137 E:1144 ||| VBZ
in  ||| S:1144 E:1147 ||| IN
these  ||| S:1147 E:1153 ||| DT
cells ||| S:1153 E:1158 ||| NNS
.  ||| S:1158 E:1160 ||| .
Invasive ||| S:1160 E:1168 ||| NNP
,  ||| S:1168 E:1170 ||| ,
migratory  ||| S:1170 E:1180 ||| NN
and  ||| S:1180 E:1184 ||| CC
wound‑healing  ||| S:1184 E:1198 ||| CD
activities  ||| S:1198 E:1209 ||| NNS
were  ||| S:1209 E:1214 ||| VBD
observed  ||| S:1214 E:1223 ||| VBN
in  ||| S:1223 E:1226 ||| IN
MDA‑MB‑231  ||| S:1226 E:1237 ||| NNP
and  ||| S:1237 E:1241 ||| CC
MCF‑10A  ||| S:1241 E:1249 ||| CD
cells  ||| S:1249 E:1255 ||| NNS
following  ||| S:1255 E:1265 ||| VBG
treatment  ||| S:1265 E:1275 ||| NN
with  ||| S:1275 E:1280 ||| IN
recombinant  ||| S:1280 E:1292 ||| JJ
human  ||| S:1292 E:1298 ||| JJ
OPG ||| S:1298 E:1301 ||| NNP
,  ||| S:1301 E:1303 ||| ,
MDK  ||| S:1303 E:1307 ||| NNP
and  ||| S:1307 E:1311 ||| CC
ApoE3  ||| S:1311 E:1317 ||| CD
proteins ||| S:1317 E:1325 ||| NNS
.  ||| S:1325 E:1327 ||| .
Additionally ||| S:1327 E:1339 ||| RB
,  ||| S:1339 E:1341 ||| ,
tube‑formation  ||| S:1341 E:1356 ||| CD
activity  ||| S:1356 E:1365 ||| NN
was  ||| S:1365 E:1369 ||| VBD
assessed  ||| S:1369 E:1378 ||| VBN
in  ||| S:1378 E:1381 ||| IN
OPG‑ ||| S:1381 E:1385 ||| NNP
,  ||| S:1385 E:1387 ||| ,
MDK‑  ||| S:1387 E:1392 ||| NNP
and  ||| S:1392 E:1396 ||| CC
ApoE3‑treated  ||| S:1396 E:1410 ||| CD
human  ||| S:1410 E:1416 ||| JJ
umbilical  ||| S:1416 E:1426 ||| JJ
vein  ||| S:1426 E:1431 ||| NN
endothelial  ||| S:1431 E:1443 ||| NN
cells  ||| S:1443 E:1449 ||| NNS
( ||| S:1449 E:1450 ||| -LRB-
HUVECs ||| S:1450 E:1456 ||| NNP
) ||| S:1456 E:1457 ||| -RRB-
.  ||| S:1457 E:1459 ||| .
We  ||| S:1459 E:1462 ||| PRP
found  ||| S:1462 E:1468 ||| VBD
that  ||| S:1468 E:1473 ||| IN
OPG ||| S:1473 E:1476 ||| NNP
,  ||| S:1476 E:1478 ||| ,
MDK  ||| S:1478 E:1482 ||| NNP
and  ||| S:1482 E:1486 ||| CC
ApoE3  ||| S:1486 E:1492 ||| CD
affected  ||| S:1492 E:1501 ||| JJ
cell  ||| S:1501 E:1506 ||| NN
motility  ||| S:1506 E:1515 ||| NNS
and  ||| S:1515 E:1519 ||| CC
tube‑formation  ||| S:1519 E:1534 ||| CD
activity ||| S:1534 E:1542 ||| NN
.  ||| S:1542 E:1544 ||| .
Since  ||| S:1544 E:1550 ||| IN
OPG  ||| S:1550 E:1554 ||| NNP
markedly  ||| S:1554 E:1563 ||| RB
affected  ||| S:1563 E:1572 ||| VBN
cell  ||| S:1572 E:1577 ||| NN
motility ||| S:1577 E:1585 ||| NN
,  ||| S:1585 E:1587 ||| ,
we  ||| S:1587 E:1590 ||| PRP
examined  ||| S:1590 E:1599 ||| VBD
the  ||| S:1599 E:1603 ||| DT
effect  ||| S:1603 E:1610 ||| NN
of  ||| S:1610 E:1613 ||| IN
senescent  ||| S:1613 E:1623 ||| JJ
conditioned  ||| S:1623 E:1635 ||| JJ
media  ||| S:1635 E:1641 ||| NNS
containing  ||| S:1641 E:1652 ||| VBG
neutralizing  ||| S:1652 E:1665 ||| JJ
OPG  ||| S:1665 E:1669 ||| NN
antibodies  ||| S:1669 E:1680 ||| NNS
on  ||| S:1680 E:1683 ||| IN
migration  ||| S:1683 E:1693 ||| NN
and  ||| S:1693 E:1697 ||| CC
wound‑healing  ||| S:1697 E:1711 ||| CD
activity ||| S:1711 E:1719 ||| NN
.  ||| S:1719 E:1721 ||| .
Our  ||| S:1721 E:1725 ||| PRP$
results  ||| S:1725 E:1733 ||| NNS
demonstrated  ||| S:1733 E:1746 ||| VBN
that  ||| S:1746 E:1751 ||| IN
IR‑induced  ||| S:1751 E:1762 ||| CD
senescent  ||| S:1762 E:1772 ||| JJ
tumor  ||| S:1772 E:1778 ||| NN
cells  ||| S:1778 E:1784 ||| NNS
influence  ||| S:1784 E:1794 ||| VBP
the  ||| S:1794 E:1798 ||| DT
tumor  ||| S:1798 E:1804 ||| NN
microenvironment  ||| S:1804 E:1821 ||| NN
by  ||| S:1821 E:1824 ||| IN
increasing  ||| S:1824 E:1835 ||| VBG
the  ||| S:1835 E:1839 ||| DT
production  ||| S:1839 E:1850 ||| NN
of  ||| S:1850 E:1853 ||| IN
cytokines ||| S:1853 E:1862 ||| NN
,  ||| S:1862 E:1864 ||| ,
such  ||| S:1864 E:1869 ||| JJ
as  ||| S:1869 E:1872 ||| IN
OPG ||| S:1872 E:1875 ||| NNP
,  ||| S:1875 E:1877 ||| ,
MDK  ||| S:1877 E:1881 ||| NNP
and  ||| S:1881 E:1885 ||| CC
ApoE3 ||| S:1885 E:1890 ||| NNP
.  ||| S:1890 E:1892 ||| .
Furthermore ||| S:1892 E:1903 ||| RB
,  ||| S:1903 E:1905 ||| ,
these  ||| S:1905 E:1911 ||| DT
data  ||| S:1911 E:1916 ||| NNS
suggest  ||| S:1916 E:1924 ||| VBP
that  ||| S:1924 E:1929 ||| IN
OPG  ||| S:1929 E:1933 ||| NNP
is  ||| S:1933 E:1936 ||| VBZ
likely  ||| S:1936 E:1943 ||| RB
a  ||| S:1943 E:1945 ||| DT
promising  ||| S:1945 E:1955 ||| JJ
target  ||| S:1955 E:1962 ||| NN
capable  ||| S:1962 E:1970 ||| NN
of  ||| S:1970 E:1973 ||| IN
reducing  ||| S:1973 E:1982 ||| VBG
the  ||| S:1982 E:1986 ||| DT
deleterious  ||| S:1986 E:1998 ||| JJ
effects  ||| S:1998 E:2006 ||| NNS
on  ||| S:2006 E:2009 ||| IN
the  ||| S:2009 E:2013 ||| DT
tumor  ||| S:2013 E:2019 ||| NN
microenvironment  ||| S:2019 E:2036 ||| NN
during  ||| S:2036 E:2043 ||| IN
radiation  ||| S:2043 E:2053 ||| NN
therapy ||| S:2053 E:2060 ||| NN
.  ||| S:2060 E:2062 ||| .
